

進行・再発非小細胞肺癌(NSCLC)初回化学療法終了後患者の維持療法・二次療法実施に関する観察研究、中間報告

堀田 勝幸¹, 木浦 勝行¹, 葉 清隆², 内藤 陽一², 岸 一馬³, 後藤 悌⁴, 大橋 靖雄⁵, 國頭 英夫⁶

岡山大学病院 呼吸器内科¹, 国立がん研究センター東病院², 虎の門病院 呼吸器センター内科・臨床腫瘍科³, 東京大学大学院医学系研究科 呼吸器内科学⁴, 東京大学大学院医学系研究科 公共健康医学専攻⁵, 三井記念病院 呼吸器内科⁶

UMIN#00006393



10079

Background

Standard care of advanced NSCLC

- First-line platinum-based chemotherapy (first-line CT)
- Second-line chemotherapy (second-line CT) after the progression of the first-line CT

Maintenance therapy after the first-line CT

- Recently, maintenance therapy has been reported to be beneficial.
- Its impact on overall survival appears to be marginal or negligible, when most patients could receive timely active second-line CT after progression.

Objective

- To investigate the proportion of patients who had progression during observation after CR/PR/SD of first-line CT actually received the second-line CT
- To elucidate factors associated with second-line CT administration in advanced NSCLC patients.

Methods

Study design

- Cohort (prospective observational) study

Primary endpoint

- Proportion of patients who received second-line CT after first-line CT

Patient inclusion

- Patients with advanced NSCLC who received platinum-based first-line CT
- From April 2010 to September 2011, at 30 institutions in Japan

Data collection

- Baseline characteristics (age, gender, ECOG-PS, smoking status, comorbidities, body mass index, histological subtype, EGFR/ALK status, CBC/chemistry at registration)
- Regimens and responses to the first/second/third-line CT (regimen, response)
- Administration of maintenance CT
- Reason for not receiving second-line CT (if it was not administered)
- Survival

Data cutoff

- Interim report describing patients with at least 6 months of follow up at April 2012

Support

- Supported by the Public Health Research Center Foundation CSPOR

Conclusions

- Preliminary results of this large observational study in Japan suggested that
 - Among the patients who did not received maintenance therapy, 25.3% missed an opportunity to receive appropriate second-line CT.
 - We could not find associated factors for not receiving second-line CT.
 - As for the patients who received maintenance therapy, 18.2% did not receive second-line CT.
 - Administration of maintenance therapy did not appear to compromise the chance to receive second-line CT.
- Further investigation is needed to identify the patients who would be less likely to receive the second-CT after disease progression, and thus would be more likely to receive benefit from maintenance therapy strategy.

Acknowledgement

This study was funded by Comprehensive Support Project for Oncology Research (CSPOR) of Public Health Research Foundation. We would like to thank patients, their families, and following institutions; Hokkaido University Hospital, KKR Sapporo Medical Center, Iwate Prefectural Central Hospital, Tohoku University Hospital, University of Tsukuba, Ibaraki Prefectural Central Hospital, Tochigi Cancer Center, Gunma Prefectural Cancer Center, Saitama Medical University International Medical Center, Saitama Cancer Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, The Cancer Institute Hospital Of JFCR, Japanese Red Cross Medical Center, Kitasato University Hospital, Kanagawa Cardiovascular and Respiratory Center, Fujisawa City Hospital, Shinshu University Hospital, Nagoya University Graduate School Of Medicine, Okayama University Hospital, Hiroshima Prefectural Hospital, Kurume University School of Medicine, Nagasaki University Hospital, Mitsui Memorial Hospital, University of Tokyo Hospital, National Cancer Center Hospital East, Toranomon Hospital, Nishigunma National Hospital, NTT Medical Center Tokyo, Teikyo University School of Medicine, National Center for Global Health and Medicine

発表者・研究責任者の利益相反開示事項

研究費の財源	□受託 ■寄付 □科学研究費 □その他()
財源の供給元	公益財団法人(ブリックヘルスリサーチセンター)
発表者氏名: 堀田 勝幸	所属/身分: 岡山大学病院 呼吸器内科 助教
金額 (年間)	該当なし 該当有りの場合: 企業名等
法人の代表	■
企業等の顧問	■
株式・エクイティ	100万円以上の利益、全株式の5%以上 ■
講演料など	50万円以上 ■ □ 日本イーライリ-
原稿料など	50万円以上 ■
寄付金	200万円以上 ■
委託研究(治験等)	総額200万円以上 ■
専門的助言・証言(裁判)	100万円以上 ■
その他	5万円以上の贈答他 ■
試験責任者氏名: 國頭 英夫	所属/身分: 三井記念病院 呼吸器内科 科長
金額 (年間)	該当なし 該当有りの場合: 企業名等
法人の代表	■
企業等の顧問	■
株式・エクイティ	100万円以上の利益、全株式の5%以上 ■
講演料など	50万円以上 □ 日本イーライリ-
原稿料など	50万円以上 ■
寄付金	200万円以上 ■
委託研究(治験等)	総額200万円以上 ■
専門的助言・証言(裁判)	100万円以上 ■
その他	5万円以上の贈答他 ■

Results

- A total of 865 eligible patients with advanced NSCLC provided patient characteristics and details of the first-line CT.
- At the time of cut off, 800 patients were assessable for response of the first-CT. A total of 572 patients had CR/PR/SD.
- Administration of the second-CT was analyzed for 506 patients who had progression after first-line CT (primary study population)
- Maintenance therapy was administered to 144 patients. Of those,
 - 7 patients did not progress.
 - of 137 patients progressed, 25 patients (18.2%) could not receive second-line CT.
- Observation with no maintenance therapy was done in 362 patients. Of those,
 - 50 patients did not progress.
 - of 312 patients progressed, 79 patients (25.3%) could not receive second-line CT.
- Decline of PS was the principal reason for not receiving second-line CT in both patients with and without maintenance CT.

Figure 1




Table 1. Patient characteristics

Characteristics	No. of patients (n=865)	%
Sex male/female	628/237	73/24
Age median (range) 70 or more	65 (24-86) 250	29
Histology Adeno Squamous NSCLC (NOS) Others	602 174 73 16	70 20 8 2
PS 0/1/2/3-4/unknown	343/449/65/7/1	40/52/7/1/0
Smoking never/ever/unknown	173/687/5	20/79/1
Comorbidities none/any	654/211	76/24
EGFR status mutant/wild/unknown	87/515/263	10/60/30
ALK-EML translocation positive negative unknown	11 42 812	1.3 4.9 93.9

Table2. Summary of first-line CT

	No. of patients	%
First-line platinum CT	865	
Cisplatin	331	38.3
Carboplatin	501	57.9
Nedaplatin	33	3.8
Accessible for response	800	
CR	4	0.5
PR	272	34.0
SD	296	37.0
PD	162	20.3
NE	66	8.2
Maintenance therapy Primary study population	194/800 144/506	24.3 28.5

Table3. Summary of Maintenance CT

	No. of patients (n=144)	%
Bevacizumab	54	38.0
Pemetrexed	51	35.9
TS-1	13	9.2
Pemetrexed+Bevacizumab	9	6.3
TS-1+Bevacizumab	7	4.9
Docetaxel	4	2.8
Gemcitabine	2	1.4
Erlotinib	1	0.7
Pemetrexed+Gefitinib	1	0.7
Other	2	1.4

Table4. Summary of second-line CT patients with confirmed progression after CR/PR/SD in first-line CT

	No maintenance therapy (n=312)		Maintenance therapy (n=137)	
	No. of patients	%	No. of patients	%
None	79	25.3	25	18.2
2nd-line CT	233	74.7	112	81.8
Docetaxel	101	32.4	42	30.7
Pemetrexed	39	12.5	23	16.8
Erlotinib	15	4.8	12	8.8
TS-1	12	3.9	3	2.2
Gemcitabine	6	1.9	8	5.8
Other	60	19.2	24	17.5

Table5. Reasons for not receiving second-line CT after progression

Reasons	(n=104)		No maintenance therapy (n=79)		Maintenance therapy (n=25)	
	(n)	%	No. of patients	%	No. of patients	%
Declined PS	64	62.0	49	62.0	15	60.0
Patient refusal	23	17.7	14	17.7	9	36.0
Death of any cause	7	7.6	6	7.6	1	4.0
Loss of follow-up and others	10	12.7	10	12.7	0	0

Table6. Characteristics of patients with or without maintenance therapy

	(n=506)	No maintenance therapy (n=362)		Maintenance therapy (n=144)	
		No. of patients	%	No. of patients	%
Sex	male/female	277/85	76.5/23.5	93/51	64.6/35.4
Age median (range) 70 or more		67 (24-86) 127	35.1	63 (34-78) 26	18.1
Histology	Adeno Squamous NSCLC (NOS) Others	216 104 34 8	59.7 28.7 9.4 2.3	126 7 11 0	87.5 4.9 7.6 0
PS	0/1/2/3-4	152/185/22/3	42.0/51.1/6.1/0.9	75/62/6/1	52.1/43.1/4.2/0.7
Smoking	never/ever/unknown	63/296/3	17.4/81.8/0.8	34/110/0	23.6/76.4/0
EGFR status	mutant/wild/unknown	23/140/199	6.4/55.0/38.7	17/100/25	11.8/69.4/18.8

Table 7. Association between baseline characteristics and administration of second-line CT yes/no(univariate analysis)

Characteristics	No maintenance therapy (n=233/129*)				Maintenance therapy (n=112/32*)			
	No. of patients	%	P	OR (95% CI)	No. of patients	%	P	OR(95% CI)
Sex	male 180/97 female 53/32	65.0/35.0 62.4/37.6	0.213	1.12 (0.679-1.849)	70/23 42/9	75.7/24.4 82.4/17.6	0.404	0.652 (0.281-1.521)
Age	≥70 <70	78/49 155/80	61.4/38.6 66.0/34.0	0.422	0.822 (0.526-1.284)	17/9 95/23	61.4/38.6 66.0/34.0	0.118 (0.184-1.134)
PS	0 1-4	102/50 131/79	67.1/32.9 62.4/37.6	0.375	1.230 (0.794-1.905)	64/11 48/21	85.3/14.7 69.6/30.4	0.028 (1.134-5.704)
Smoking	never ever	40/23 193/106	63.4/36.6 64.5/35.5	0.886	0.955 (0.545-1.673)	32/2 80/30	94.1/5.9 72.7/27.3	0.009 (1.492-23.84)
Comorbidities	none yes	173/93 60/36	65.0/35.0 62.5/37.5	0.710	1.116 (0.689-1.807)	90/24 22/8	72.6/28.4 73.3/26.7	0.622 (0.552-3.388)
Platinum regimen	CDDP other	92/41 141/88	69.1/30.9 61.6/38.4	0.172	1.400 (0.890-2.202)	42/8 70/24	84.0/16.0 74.5/25.5	0.213 (0.753-4.283)

Patients without progression of first-line CT are included